These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 24567430)

  • 1. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
    Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
    J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.
    Hurry M; Zhou ZY; Zhang J; Zhang C; Fan L; Rebeira M; Xie J
    J Med Econ; 2016 Oct; 19(10):936-44. PubMed ID: 27149298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
    Lu S; Yu Y; Fu S; Ren H
    PLoS One; 2018; 13(10):e0205827. PubMed ID: 30352060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
    J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
    Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
    J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
    Carlson JJ; Canestaro W; Ravelo A; Wong W
    J Med Econ; 2017 Jul; 20(7):671-677. PubMed ID: 28332433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost?
    Kelly RJ; Hillner BE; Smith TJ
    J Clin Oncol; 2014 Apr; 32(10):983-5. PubMed ID: 24567437
    [No Abstract]   [Full Text] [Related]  

  • 11. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
    Beca JM; Walsh S; Raza K; Hubay S; Robinson A; Mow E; Keech J; Chan KKW
    BMC Cancer; 2021 Oct; 21(1):1162. PubMed ID: 34715804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI; Gautschi O
    Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.
    Robesova B; Bajerova M; Hausnerova J; Skrickova J; Tomiskova M; Dvorakova D
    Lung Cancer; 2015 Mar; 87(3):318-20. PubMed ID: 25601488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
    Nilsson RJ; Karachaliou N; Berenguer J; Gimenez-Capitan A; Schellen P; Teixido C; Tannous J; Kuiper JL; Drees E; Grabowska M; van Keulen M; Heideman DA; Thunnissen E; Dingemans AM; Viteri S; Tannous BA; Drozdowskyj A; Rosell R; Smit EF; Wurdinger T
    Oncotarget; 2016 Jan; 7(1):1066-75. PubMed ID: 26544515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New targets in advanced NSCLC: EML4-ALK.
    Crystal AS; Shaw AT
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.
    Wang Y; Zhang J; Gao G; Li X; Zhao C; He Y; Su C; Zhang S; Chen X; Zhang J; Li W; Li B; Zhao J; Hou L; Wu C; Ren S; Zhou C; Zhang J
    J Thorac Oncol; 2015 Nov; 10(11):1546-52. PubMed ID: 26352533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM; Rudin CM
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.